Multiple Sclerosis – Current Treatment – Detailed, Expanded Analysis (US)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes. Most recently, TG Therapeutics launched Briumvi, the third-in-class anti-CD20 monoclonal antibody. Given the rapid pace of expansion in the MS market, developers of both current and emerging DMTs must continually reassess their products’ differentiation and likely positioning in this highly competitive space. This report will explore neurologists’ perceptions of established and recently launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as more DMTs expand—and further complicate—prescriber choice.
Questions answered
- How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting, secondary-progressive, and primary-progressive) treated today?
- How do product shares differ across lines of therapy? Are high-efficacy therapies (e.g., Ocrevus) factoring more into early-line treatment decisions?
- How are the S1P receptor modulator and anti-CD20 classes changing with expansion?
- How has neurologists’ prescribing changed in the past year, and why? What further changes do they expect within the next year?
- What are neurologists’ opinions of the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 U.S. neurologists
Key drugs covered: Aubagio, Briumvi, glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera, Tysabri, Vumerity, Zeposia
Key companies: Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Roche, Sanofi Genzyme, TG Therapeutics
Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for changes in treatment approach.
- Physician insight on persistency and compliance.
- Physician-reported recent/anticipated changes in brand usage or treatment approach.
Table of contents
- Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights-Multiple Sclerosis-US-May 2023
Grant Nix, M.B.A., Healthcare Research & Data Analyst. His focus is the multiple sclerosis market. In this role, he conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including multiple sclerosis. Prior to joining Clarivate, he worked as an operations analyst at UNC Health, positioned on a behavioral health unit. He earned his M.B.A. at North Carolina Central University, where he specialized in finance. He also holds a B.S. in chemistry from Campbell University.